Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters

Rev Esp Enferm Dig. 2022 Jun;114(6):312-313. doi: 10.17235/reed.2022.8902/2022.

Abstract

The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liver transplantation (LT).

Publication types

  • Introductory Journal Article
  • Editorial
  • Comment

MeSH terms

  • Drug Therapy, Combination
  • Everolimus* / therapeutic use
  • Humans
  • Kidney / drug effects
  • Kidney / physiology
  • Liver Transplantation*
  • Multicenter Studies as Topic
  • Mycophenolic Acid* / therapeutic use
  • Tacrolimus / therapeutic use

Substances

  • Everolimus
  • Mycophenolic Acid
  • Tacrolimus